Today Sep 22, 2021
Event Image
Back to Events

Conversations in Hematology: How will the data presented at ASCO impact community practice?

Wednesday Sep 08, 2021
Event Time 12:15 - 12:45 PM ET
Registration Closed
Faculty
Event Faculty

Jennifer Brown, MD, PhD

Professor, Medicine
Harvard Medical School
Director, CLL Center
Dana-Farber Cancer Institute
Boston, MA
Event Faculty

Tara Graff, DO

Medical Oncologist
Mission Cancer and Blood
Des Moines, IA

Description:
Bruton Tyrosine Kinase (BTK) Inhibitors have recently changed the treatment of CLL, but the efficacy of first-generation agents has been limited by relatively high adverse event and treatment discontinuation rates. Acalabrutinib, a selective, next-generation covalent BTK inhibitor approved for the treatment of patients with treatment-naive and relapsed/refractory CLL/small lymphocytic lymphoma (SLL), is hypothesized to have enhanced tolerability vs first-generation agents. Join Dr. Jennifer Brown and Dr. Tara Graff in this engaging webinar as they discuss the clinical implications of recent data on the efficacy and safety of acalabrutinib for the treatment of CLL from ASCO 2021.

Learning Objectives:
*Review the efficacy of acalabrutinib in treatment-naïve and previously treated chronic lymphocytic leukemia
*Review the safety and tolerability of acalabrutinib in treatment-naïve and previously treated chronic lymphocytic leukemia
*Integrate new data into the development of treatment plans for chronic lymphocytic leukemia

Event Sponsors

The content for this program has been independently developed by Clinical Care Solutions.